3% saline versus mannitol in the treatment of cerebral edema in children: a randomized controlled trial
DOI:
https://doi.org/10.18203/2349-3291.ijcp20262962Keywords:
Cerebral edema, Children, Hypertonic saline, Mannitol, Pediatric intensive care, Randomized controlled trial, Raised intracranial pressureAbstract
Background: Cerebral edema with raised intracranial pressure is a pediatric neurological emergency associated with coma, herniation and death. Mannitol and hypertonic saline are commonly used osmotic agents, but comparative pediatric data remain limited and heterogeneous. To compare the efficacy and safety of 3% hypertonic saline with 20% mannitol in children aged 3 months to 12 years with cerebral edema.
Methods: This randomized controlled trial was conducted from 2023 to 2025 among 70 children with clinical or radiological evidence of cerebral edema. Eligible children were randomized equally into the mannitol group (n=35) and 3% saline group (n=35). Mannitol was administered as 20% mannitol at 1.5 ml/kg intravenously over 20 minutes every 8 hours, whereas 3% saline was administered at 5 ml/kg intravenously over 20 minutes every 8 hours. Other supportive management was standardized. Outcomes included early Glasgow Coma Scale improvement, time to recovery from coma, duration of ventilation, survival and treatment-related complications.
Results: Baseline age, sex, nutritional status, admission GCS, etiology and diagnostic features were comparable between groups. Early GCS improvement of at least 2 points within 6 hours occurred in 23 children (65.7%) in the 3% saline group compared with 13 children (37.1%) in the mannitol group (p=0.031). Coma duration ≤24 hours was observed in 18 children (51.4%) receiving 3% saline and 9 children (25.7%) receiving mannitol (p=0.026). Ventilation duration ≤24 hours was more frequent with 3% saline (14 (40.0%)) than mannitol (6 (17.1%)) (p=0.034). Survival was higher in the 3% saline group (32 (91.4%)) than in the mannitol group (26 (74.3%)), but this difference was not statistically significant (p=0.110). Hypernatremia was more frequent with 3% saline (9 (25.7%) vs 2 (5.7%); p=0.045), while renal dysfunction was numerically more frequent with mannitol (5 (14.3%) vs 1 (2.9%); p=0.198).
Conclusions: In children with cerebral edema, 3% hypertonic saline was associated with faster early neurological improvement and shorter coma and ventilation duration compared with mannitol, while mortality difference was not statistically significant. Hypernatremia requires close monitoring during hypertonic saline therapy.
References
Cook AM, Morgan Jones G, Hawryluk GWJ, Mailloux P, McLaughlin D, Papangelou A, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocrit Care. 2020;32(3):647-66.
Kochanek PM, Tasker RC, Carney N, Totten AM, Adelson PD, Selden NR, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines. Pediatr Crit Care Med. 2019;20(1):1-82.
Rameshkumar R, Bansal A, Singhi S, Singhi P, Jayashree M. Randomized clinical trial of 20% mannitol versus 3% hypertonic saline in children with raised intracranial pressure due to acute CNS infections. Pediatr Crit Care Med. 2020;21(12):1071-80.
Upadhyay P, Tripathi VN, Singh RP, Sachan D. Role of hypertonic saline and mannitol in the management of raised intracranial pressure in children: a randomized comparative study. J Pediatr Neurosci. 2010;5(1):18-21.
Mishra NR, Agrawal A, Das RR. Hypertonic saline vs. mannitol in management of elevated intracranial pressure in children: a meta-analysis. Indian J Pediatr. 2023;90(9):899-906.
Choudhury A, Ravikant, Bairwa M, Jithesh G, Kumar S, Kumar N. Efficacy of intravenous 20% mannitol vs 3% hypertonic saline in reducing intracranial pressure in nontraumatic brain injury: a systematic review and meta-analysis. Indian J Crit Care Med. 2024;28(7):686-95.
Kochanek PM, Adelson PD, Rosario BL. ADAPT Investigators. Comparison of intracranial pressure measurements before and after hypertonic saline or mannitol treatment in children with severe traumatic brain injury. JAMA Netw Open. 2022;5(3):891.
Chong SL, Zhu Y, Wang Q. Pediatric Acute and Critical Care Medicine in Asia Network (PACCMAN) and Red Colaborativa Pediatrica de Latinoamerica (LARed). Clinical outcomes of hypertonic saline vs mannitol treatment among children with traumatic brain injury. JAMA Netw Open. 2025;8(3):250438.
Rodrigues M, Grilo M, Baptista MJ. Hyperosmolar therapy in pediatric traumatic brain injury: a systematic review. J Pediatr Neonatal Individ Med. 2023;12(2):206.
Afroze F, Taha A, Yousuf S. Effect of hypertonic saline in the management of elevated intracranial pressure in children with cerebral edema: a systematic review. Cureus. 2021;13(3):4175.
Wellard J, Kuwabara M, Adelson PD, Appavu B. Physiologic characteristics of hyperosmolar therapy after pediatric traumatic brain injury. Front Neurol. 2021;12:662089.
Zipfel J, Engel J, Hockel K, Heimberg E, Schuhmann MU, Neunhoeffer F. Effects of hypertonic saline on intracranial pressure and cerebral autoregulation in pediatric traumatic brain injury. J Neurosurg Pediatr. 2021;28(6):631-7.
Ha EJ. Pediatric severe traumatic brain injury: updated management. J Korean Neurosurg Soc. 2022;65(3):341-52.
Susanto M, Riantri I. Optimal dose and concentration of hypertonic saline in traumatic brain injury: a systematic review. Medeni Med J. 2022;37(2):203-211.
Schwimmbeck F, Voellger B, Chappell D, Eberhart L. Hypertonic saline versus mannitol for traumatic brain injury: a systematic review and meta-analysis with trial sequential analysis. J Neurosurg Anesthesiol. 2021;33(1):10-20.
Karamian A, Seifi A, Lucke-Wold B. Comparing the effects of mannitol and hypertonic saline in severe traumatic brain injury patients with elevated intracranial pressure: a systematic review and meta-analysis. Neurol Res. 2024;46(9):883-92.
Upadhyay S, Agrawal J, Kafle S, Shrestha M. Comparision between 3% hypertonic saline and 20% mannitol in the management of raised intracranial pressure in children. Int J Adv Multidiscip Res Stud. 2024;4(2):452-7.
Kochar I. Comparative evaluation of 3% hypertonic saline versus 20% mannitol in pediatric patients with raised intracranial pressure. Int J Med Public Health. 2025;15(3):664-6.
Ortiz MH. Efficacy of 20% mannitol versus 3% hypertonic saline in achieving decreased intracranial pressure in pediatric patients: a systematic review. PIDSP J. 2022;23(2):20-9.
Bernhardt K, McClune W, Rowland MJ, Shah A. Hypertonic saline versus other intracranial-pressure-lowering agents for patients with acute traumatic brain injury: a systematic review and meta-analysis. Neurocrit Care. 2024;40(2):589-602.
Gharizadeh N, Hatamabadi H, Khoshnevisan A. Hypertonic saline for traumatic brain injury: a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2022;30(1):69.
Downloads
Published
How to Cite
Issue
Section
